Public Sector Pension Investment Board Sells 1,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Public Sector Pension Investment Board trimmed its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 53,656 shares of the company’s stock after selling 1,000 shares during the quarter. Public Sector Pension Investment Board’s holdings in Krystal Biotech were worth $9,767,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Key Financial Inc purchased a new stake in shares of Krystal Biotech during the second quarter valued at approximately $28,000. GAMMA Investing LLC boosted its stake in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the last quarter. Jamison Private Wealth Management Inc. bought a new stake in shares of Krystal Biotech in the 2nd quarter worth $28,000. Blue Trust Inc. raised its stake in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Krystal Biotech in the third quarter worth $53,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 14.10% of the company’s stock.

Krystal Biotech Trading Up 0.3 %

Shares of KRYS stock opened at $197.42 on Friday. Krystal Biotech, Inc. has a 12 month low of $100.78 and a 12 month high of $219.34. The stock has a market cap of $5.68 billion, a P/E ratio of 111.54 and a beta of 0.82. The company has a 50 day simple moving average of $180.49 and a two-hundred day simple moving average of $183.58.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same period last year, the firm earned ($0.67) EPS. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Chardan Capital lifted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Tuesday, November 5th. Finally, Stifel Nicolaus boosted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $202.29.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).